From Genotype to Phenotype: The Differential Expression of FGF, FGFR, and TGFβ Genes Characterizes Human Cranioskeletal Development and Reflects Clinical Presentation in FGFR Syndromes
- 1 December 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 108 (7) , 2026-2039
- https://doi.org/10.1097/00006534-200112000-00030
Abstract
Mutations in the fibroblast growth factor receptor (FGFR) genes 1, 2, and 3 are causal in a number of craniofacial dysostosis syndromes featuring craniosynostosis with basicranial and midfacial deformity. Great clinical variability is displayed in the pathologic phenotypes encountered. To investigate the influence of developmental genetics on clinical diversity in these syndromes, the expression of several genes implicated in their pathology was studied at sequential stages of normal human embryofetal cranial base and facial ossification (n = 6). At 8 weeks of gestation, FGFR1, FGFR2, and FGFR3 are equally expressed throughout the predifferentiated mesenchyme of the cranium, the endochondral skull base, and midfacial mesenchyme. Both clinically significant isoforms of FGFR2, IgIIIa/c and IgIIIa/b, are coexpressed in maxillary and basicranial ossification. By 10 to 13 weeks, FGFR1 and FGFR2 are broadly expressed in epithelia, osteogenic, and chondrogenic cell lineages. FGFR3, however, is maximally expressed in dental epithelia and proliferating chondrocytes of the skull base, but poorly expressed in the osteogenic tissues of the midface. FGF2 and FGF4, but not FGF7, and TGFβ1 and TGFβ3 are expressed throughout both osteogenic and chondrogenic tissues in early human craniofacial skeletogenesis. Maximal FGFR expression in the skull base proposes a pivotal role for syndromic growth dysplasia at this site. Paucity of FGFR3 expression in human midfacial development correlates with the relatively benign human mutant FGFR3 midfacial phenotypes. The regulation of FGFR expression in human craniofacial skeletogenesis against background excess ligand and selected cofactors may therefore play a profound role in the pathologic craniofacial development of children bearing FGFR mutations. (Plast. Reconstr. Surg. 108: 2026, 2001.)Keywords
This publication has 86 references indexed in Scilit:
- Differential Expression of Fibroblast Growth Factor Receptors in Human Digital Development Suggests Common Pathogenesis in Complex Acrosyndactyly and CraniosynostosisPlastic and Reconstructive Surgery, 2001
- Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligandHuman Molecular Genetics, 1998
- Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domainProceedings of the National Academy of Sciences, 1998
- Fibroblast growth factor receptors: lessons from the genesTrends in Biochemical Sciences, 1998
- Spectrum of Craniosynostosis Phenotypes Associated with Novel Mutations at the Fibroblast Growth Factor Receptor 2 LocusEuropean Journal of Human Genetics, 1996
- Chronic tonsillar herniation in Crouzon's and Apert's syndromes: the role of premature synostosis of the lambdoid sutureJournal of Neurosurgery, 1995
- Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndromeNature Genetics, 1995
- Comparative three-dimensional analysis of CT-scans of the calvaria and cranial base in Apert and Crouzon syndromesJournal of Cranio-Maxillofacial Surgery, 1993
- Craniosynostosis, midfacial hypoplasia, and foot abnormalities: An autosomal dominant phenotype in a large Amish kindredThe Journal of Pediatrics, 1976
- Dominant erbliche AkrocephalosyndaktylieEuropean Journal of Pediatrics, 1964